173 related articles for article (PubMed ID: 7486915)
1. Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.
Hong YL; Hossler PA; Calhoun DH; Meshnick SR
Antimicrob Agents Chemother; 1995 Aug; 39(8):1756-63. PubMed ID: 7486915
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of sulfa drugs against recombinant Pneumocystis carinii dihydropteroate synthetase and in vivo.
Hong YL; Hossler P; Bartlett M; Queener S; Smith J; Meshnick S
J Eukaryot Microbiol; 1996; 43(5):40S. PubMed ID: 8822843
[No Abstract] [Full Text] [Related]
3. Inhibition of Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.
Merali S; Zhang Y; Sloan D; Meshnick S
Antimicrob Agents Chemother; 1990 Jun; 34(6):1075-8. PubMed ID: 2203302
[TBL] [Abstract][Full Text] [Related]
4. Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium.
Chio LC; Bolyard LA; Nasr M; Queener SF
Antimicrob Agents Chemother; 1996 Mar; 40(3):727-33. PubMed ID: 8851601
[TBL] [Abstract][Full Text] [Related]
5. Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone).
Voeller D; Kovacs J; Andrawis V; Chu E; Masur H; Allegra C
J Infect Dis; 1994 Feb; 169(2):456-9. PubMed ID: 8106784
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: possible mechanism of action of isoprinosine in human immunodeficiency virus infection.
Kovacs JA; Powell F; Voeller D; Allegra CJ
Antimicrob Agents Chemother; 1993 Jun; 37(6):1227-31. PubMed ID: 7687120
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Plasmodium falciparum dihydropteroate synthetase and growth in vitro by sulfa drugs.
Zhang Y; Meshnick SR
Antimicrob Agents Chemother; 1991 Feb; 35(2):267-71. PubMed ID: 2024960
[TBL] [Abstract][Full Text] [Related]
8. Quantitative structure-activity relationship studies of a series of sulfa drugs as inhibitors of Pneumocystis carinii dihydropteroate synthetase.
Johnson T; Khan IA; Avery MA; Grant J; Meshnick SR
Antimicrob Agents Chemother; 1998 Jun; 42(6):1454-8. PubMed ID: 9624493
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients.
Armstrong W; Meshnick S; Kazanjian P
Microbes Infect; 2000 Jan; 2(1):61-7. PubMed ID: 10717542
[TBL] [Abstract][Full Text] [Related]
10. Sulfa resistance and dihydropteroate synthase mutants in recurrent Pneumocystis carinii pneumonia.
Nahimana A; Rabodonirina M; Helweg-Larsen J; Meneau I; Francioli P; Bille J; Hauser PM
Emerg Infect Dis; 2003 Jul; 9(7):864-7. PubMed ID: 12890330
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients.
Kazanjian P; Locke AB; Hossler PA; Lane BR; Bartlett MS; Smith JW; Cannon M; Meshnick SR
AIDS; 1998 May; 12(8):873-8. PubMed ID: 9631140
[TBL] [Abstract][Full Text] [Related]
12. Sulfa resistance in mouse-derived Pneumocystis carinii.
Lane B; Hossler P; Bartlett M; Queener S; O'Reilly T; Smith J; Meshnick S
J Eukaryot Microbiol; 1996; 43(5):39S. PubMed ID: 8822842
[No Abstract] [Full Text] [Related]
13. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use.
Ma L; Borio L; Masur H; Kovacs JA
J Infect Dis; 1999 Dec; 180(6):1969-78. PubMed ID: 10558954
[TBL] [Abstract][Full Text] [Related]
14. Pneumocystis carinii dihydropteroate synthase mutations and treatment with sulfa or sulfone regimens: a proposal for standardized definitions for clinical evaluation.
Huang L; Morris AM; Beard CB
J Eukaryot Microbiol; 2001; Suppl():180S-181S. PubMed ID: 11906054
[No Abstract] [Full Text] [Related]
15. The multifunctional folic acid synthesis fas gene of Pneumocystis carinii encodes dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase.
Volpe F; Ballantine SP; Delves CJ
Eur J Biochem; 1993 Sep; 216(2):449-58. PubMed ID: 8397083
[TBL] [Abstract][Full Text] [Related]
16. Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy.
Takahashi T; Hosoya N; Endo T; Nakamura T; Sakashita H; Kimura K; Ohnishi K; Nakamura Y; Iwamoto A
J Clin Microbiol; 2000 Sep; 38(9):3161-4. PubMed ID: 10970350
[TBL] [Abstract][Full Text] [Related]
17. Drug-resistant Pneumocystis carinii.
Meshnick SR
Lancet; 1999 Oct; 354(9187):1318-9. PubMed ID: 10533856
[No Abstract] [Full Text] [Related]
18. Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs.
Iliades P; Meshnick SR; Macreadie IG
Antimicrob Agents Chemother; 2005 Feb; 49(2):741-8. PubMed ID: 15673759
[TBL] [Abstract][Full Text] [Related]
19. Absence of mutations associated with sulfa resistance in Pneumocystis carinii dihydropteroate synthase gene from non-human primates.
Demanche C; Guillot J; Berthelemy M; Petitt T; Roux P; Wakefield AE
Med Mycol; 2002 Jun; 40(3):315-8. PubMed ID: 12146763
[TBL] [Abstract][Full Text] [Related]
20. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia.
Kovacs JA; Gill VJ; Meshnick S; Masur H
JAMA; 2001 Nov; 286(19):2450-60. PubMed ID: 11712941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
